Christopher H. SchottPartner at Hogan Lovells
Christopher H. Schott advises clients in the pharmaceutical industry in connection with drug price reporting and other compliance obligations. His practice focuses on the Medicaid, Medicare, and 340B Drug Pricing programs.
Chris helps pharmaceutical manufacturers apply price reporting and compliance requirements under these Department of Health & Human Services (HHS) programs to their particular business models and commercial approaches, both in terms of ongoing compliance through the development of methodologies and reasonable assumptions, as well as with respect to evaluating specific commercial pricing or contracting strategies and initiatives. Chris also assists pharmaceutical manufacturers that seek to engage with federal regulators regarding these programs, whether as to public policy proposals generally, through comment drafting and in-person advocacy, or where a manufacturer seeks guidance regarding specific commercial proposals and how the regulators may view those proposals under program standards. He also supports manufacturers in connection with state price reporting obligations.
Chris translates this regulatory expertise into more broad commercial support for pharmaceutical manufacturers. He regularly helps clients evaluate the impact of HHS program requirements on proposed M&A transactions and advises on due diligence matters and the post-closing transition of regulatory responsibilities under these programs. Chris also regularly advises pharmaceutical manufacturers regarding industry-specific price reporting aspects of their periodic reporting obligations under the U.S. federal securities laws.
Prior to joining Hogan Lovells, Chris was an associate at a leading national law firm, where he represented Wall Street financial institutions and investment banks. Chris was employed in the telecommunication and information technology sectors before and while attending the George Washington University Law School.
In law school, Chris was a George Washington Scholar and a member of The George Washington International Law Review. He is a recipient of the law school's Richard L. Teberg Award for Excellence in securities law.